Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. DexCom, Inc.
  6. News
  7. Summary
    DXCM   US2521311074

DEXCOM, INC.

(DXCM)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
321.23 USD   +1.62%
05/20DEXCOM INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/17Citigroup Adjusts DexCom's Price Target to $525 From $630, Reiterates Buy Rating
MT
05/11TRANSCRIPT : DexCom, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 02:40 PM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Sell: Dexcom

01/21/2022 | 06:42am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about DEXCOM, INC.
05/20DEXCOM INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/17Citigroup Adjusts DexCom's Price Target to $525 From $630, Reiterates Buy Rating
MT
05/11TRANSCRIPT : DexCom, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2..
CI
05/10Dexcom Announces Upcoming Conference Presentations
BU
04/29Raymond James Adjusts DexCom's Price Target to $486 From $538, Keeps Outperform Rating
MT
04/29Morgan Stanley Adjusts Price Target for DexCom to $492 From $514, Maintains Equalweigh..
MT
04/29SVB Leerink Adjusts DexCom's Price Target to $500 From $565, Keeps Outperform Rating
MT
04/29Piper Sandler Adjusts DexCom's Price Target to $480 From $725, Reiterates Overweight Ra..
MT
04/28DEXCOM : Reports First Quarter 2022 Financial Results - Form 8-K
PU
04/28DEXCOM INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF ..
AQ
More news
Analyst Recommendations on DEXCOM, INC.
More recommendations
Financials (USD)
Sales 2022 2 917 M - -
Net income 2022 380 M - -
Net cash 2022 63,8 M - -
P/E ratio 2022 86,4x
Yield 2022 -
Capitalization 31 521 M 31 521 M -
EV / Sales 2022 10,8x
EV / Sales 2023 8,98x
Nbr of Employees 6 300
Free-Float 99,5%
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 321,23 $
Average target price 528,29 $
Spread / Average Target 64,5%
EPS Revisions
Managers and Directors
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Jereme M Sylvain Chief Financial Officer & EVP-Finance
Andrew K. Balo EVP-Global Medical Affairs, Access & Evidence
Jacob S. Leach Chief Technology Officer & Executive VP
Donald M. Abbey Executive VP-IT, Quality & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
DEXCOM, INC.-40.18%31 521
ABBOTT LABORATORIES-19.54%196 876
MEDTRONIC PLC-0.89%137 843
BECTON, DICKINSON AND COMPANY2.66%71 591
BAXTER INTERNATIONAL INC.-14.69%36 556
HOYA CORPORATION-26.33%36 134